Home | Coriolis Pharma

Coriolis Pharma Formulating innovation

For us innovation is progress achieved by collaboration. We generate innovation by combining technologies, knowledge and experience.

Formulating for us means to find the right solution.

Read More

About us

Coriolis is a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs and vaccines.

As a family-owned and independent company with an interdisciplinary team of highly skilled scientists and an expert scientific advisory board, we provide cutting-edge services and tailor-made solutions for our customers.

Formulation Development

Formulation Development

“It is a medicine, not a molecule, that we are giving to the patient” Marc B. Brown, 2005.

Coriolis is the expert in developing liquid and lyophilized formulations for a large variety of different (bio)pharmaceutical molecules.

Find out how we can support your drug development...

Read more

Analytical Capabilities

Analytical Capabilities

A highly diverse analytical portfolio entirely performed in-house: This is Coriolis.

With the latest in technology and highly experienced scientists, we are a trendsetter in the field.

Get to know our services...

Read more

About us

About us

Independent, reliable and always on the cutting edge of science. Coriolis is the leading service provider for formulation research and development of (bio)pharmaceutical drugs and vaccines.

Get to know us...

Read more

Latest news

Coriolis CSO will talk at PDA workshop in Sweden

Get to know us at the InPharma Symposium in Munich

Coriolis will be present at PDA Europe event in Berlin

Coriolis CTO present at conference in Munich

Coriolis scientist speaks at AATP Conference in Paris

Coriolis participates at the Nordic Life Science (NLS) Days

Coriolis participates at the BioManufacturing Conference Europe

Coriolis CTO and scientific advisors speak at seminar in Tokyo

Coriolis scientists give talks at international conference in Boston

Sponsoring the 2019 Colorado Protein Stability Conference

Latest publications

Stress Factors in Monoclonal Antibody Drug Substance Production Processes: Critical Assessment of Impact on Product Quality and Control Strategy.

Das TK, Narhi LO, Sreedhara A, Menzen T, Grapentin C, Chou DK, Antochshuk V, Filipe V.

Shifting Paradigms Revisited: Biotechnology and the Pharmaceutical Sciences

Crommelin D, Nastribattusta E, Hawe A, Hoogendoorn K and Jiskoot W.

Immunogenicity of therapeutic proteins.

Jiskoot W, Rispens T and Kijanka G.

Biophysical and biochemical characteristics of therapeutic proteins.

Jiskoot W and Crommelin DJA.

Jiskoot W, Kersten GFA, Mastrobattista E and Slütter B.

Formulation of biologicals including biopharmaceutical considerations.

Crommelin DJA, Hawe A and Jiskoot W .

Backgrounded Membrane Imaging (BMI) for High-Throughput Characterization of Subvisible Particles During Biopharmaceutical Drug Product Development.

Helbig C, Ammann G, Menzen T, Friess W, Wuchner K, Hawe A.

Comparison of ice fog methods and monitoring of controlled nucleation success after freeze-drying.

Vollrath I, Friess W, Freitag A, Hawe A, Winter G.

Test models for the evaluation of immunogenicity of protein aggregates.

Kraus T, Winter G, Engert J.

Silicone Oil-Free Polymer Syringes for the Storage of Therapeutic Proteins.

Werner BP, Schöneich C, Winter C.